Patents Examined by Shulamith H. Shafer
-
Patent number: 10822382Abstract: Liposomal and/or nano-liposomal encapsulated peptides of HSP90a, HPf polypeptide (115 aa) and novel polypeptides HPf?C1 (101 aa) and HPf?C2 (87 aa), and methods for manufacturing/preparing and using the compositions, are disclosed. Chimeric fusion proteins that include HSP90a, HPf, HPf?C, HPf?C2 polypeptide, or combinations thereof, are presented. Transformed cell lines and expression vectors capable of expressing the chimeric fusion proteins, are provided. Methods for producing large amounts of recombinant HSP90a, HPf polypeptide, HPf?C1 or HPf?C2 polypeptide, using expression vectors and transformed cell lines, are described.Type: GrantFiled: April 12, 2018Date of Patent: November 3, 2020Assignee: Regeron, Inc.Inventors: Kibum Nam, Kyunyoung Lee, Youngwook Cho, Dahlkyun Oh
-
Patent number: 10813996Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: GrantFiled: May 7, 2018Date of Patent: October 27, 2020Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT AT MAINZ GEMEINNUTZIGE GMBHInventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
-
Patent number: 10808029Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: GrantFiled: February 9, 2017Date of Patent: October 20, 2020Assignee: Glaxo Group LimitedInventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
-
Patent number: 10800834Abstract: Provided herein are HER-3, HER-1 and IGF-1R B cell epitopes, peptide mimics, chimeric peptides and multivalent peptides. In some embodiments, the chimeric peptides include one or more HER-3, HER-1 and/or IGF-1R B cell epitopes, a linker, and a T helper cell (Th cell) epitope. Pharmaceutical compositions are also provided that contain one or more HER-3, HER-1 and/or IGF-1R chimeric peptides, and optionally, one or more HER-2 chimeric peptides and/or VEGF peptides. Also included herein are methods of treating a cancer using the HER-3, HER-1 and IGF-1R B cell epitopes, chimeric peptides and multivalent peptides.Type: GrantFiled: March 4, 2019Date of Patent: October 13, 2020Assignee: Ohio State Innovation FoundationInventor: Pravin T. P. Kaumaya
-
Patent number: 10766942Abstract: The present invention provides an anti-angiogenic peptide comprising an amino acid sequence having at least 70% identity to amino acid residues 123-140 of SEQ ID NO 1 or amino acid residues 24-141 of SEQ ID NO 2. The invention also provides nucleic acid constructs encoding such peptides, and vectors and cells comprising such nucleic acid constructs. The invention further provides pharmaceutical compositions comprising the peptides or nucleic acid constructs of the invention, and the use of peptides, nucleic acid constructs or pharmaceutical compositions of the invention to treat diseases associated with angiogenesis.Type: GrantFiled: October 20, 2015Date of Patent: September 8, 2020Assignee: Queen Mary University of LondonInventors: James Whiteford, Giulia De Rossi
-
Patent number: 10758621Abstract: The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.Type: GrantFiled: March 15, 2018Date of Patent: September 1, 2020Assignees: Amgen Research (Munich) GmbH, Takeda GmbHInventors: Thomas Urbig, Thomas Boehm, Wolfram Steinhilber, Michael Molhoj
-
Patent number: 10738096Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.Type: GrantFiled: July 27, 2017Date of Patent: August 11, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: K. Christopher Garcia, Darren L. Bates, Ignacio Moraga
-
Patent number: 10738113Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.Type: GrantFiled: September 18, 2018Date of Patent: August 11, 2020Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, PFIZER INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
-
Patent number: 10723797Abstract: The present invention relates to methods for treating psoriasis and other indications by inhibiting leptin activity.Type: GrantFiled: June 3, 2019Date of Patent: July 28, 2020Assignee: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Eran Elinav
-
Patent number: 10717784Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.Type: GrantFiled: January 9, 2018Date of Patent: July 21, 2020Assignee: NOVO NORDISK A/SInventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
-
Patent number: 10717785Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury disease.Type: GrantFiled: February 23, 2018Date of Patent: July 21, 2020Assignee: BROTEIO PHARMA B.V.Inventors: Cornelis Erik Hack, Cafer Yildiz, Louis Boon, Petrus Johannes Simons
-
Patent number: 10718765Abstract: Biomarkers useful for assessing inflammatory disease or flare activity, in particular in juvenile idiopathic arthritis, are provided, along with kits for measuring expression of the biomarkers. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.Type: GrantFiled: September 30, 2016Date of Patent: July 21, 2020Assignee: CRESCENDO BIOSCIENCE, INC.Inventors: Scott Eastman, Eric Sasso
-
Patent number: 10709799Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: January 19, 2018Date of Patent: July 14, 2020Assignee: CytomX Therapeutics, Inc.Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Patent number: 10695425Abstract: Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of removing IgG from blood of the subject, blocking IgG from activating VGCCs in the subject; or blocking VGCCs in the subject are described, as are methods for identifying ALS patients at risk of developing diabetes.Type: GrantFiled: April 20, 2018Date of Patent: June 30, 2020Assignee: Biocrine ABInventor: Per-Olof Berggren
-
Patent number: 10696746Abstract: There is disclosed compositions and methods relating to or derived from anti-CCR2 antibodies. More specifically, there is disclosed fully human antibodies that bind CCR2, CCR2-binding fragments and derivatives of such antibodies, and CCR2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CCR2 related disorders or conditions.Type: GrantFiled: March 19, 2018Date of Patent: June 30, 2020Assignee: Sorrento Therapeutics, Inc.Inventors: Dingqiu Huang, Barbara A. Swanson, John Dixon Gray, Heyue Zhou, Guodi Lu
-
Patent number: 10682416Abstract: Provided herein, inter alia, are compositions and kits comprising epicardial-derived paracrine factors (such as, hypoglycosylated follistatin-like 1 (FSTL1)) for treating and repairing damage to cardiac tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or cardiac-growth deficiency, as well as methods for using the same.Type: GrantFiled: April 8, 2016Date of Patent: June 16, 2020Assignees: Regencor, Inc., Sanford Burnham Prebys Medical Discovery InstituteInventors: Pilar Ruiz-Lozano, Mark Mercola, Ke Wei
-
Patent number: 10677804Abstract: Methods and kits for diagnosing arthritis are provided. The methods may involve detection of 14-3-3 eta or gamma proteins in a sera or synovial fluid sample.Type: GrantFiled: October 16, 2017Date of Patent: June 9, 2020Assignee: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Aziz Ghahary, Wolodymyr Walter Peter Maksymowych, Ruhangiz Taghi Kilani
-
Patent number: 10660971Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.Type: GrantFiled: December 20, 2017Date of Patent: May 26, 2020Assignee: Birdie Biopharmaceuticals, Inc.Inventor: Lixin Li
-
Patent number: 10646550Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.Type: GrantFiled: January 25, 2018Date of Patent: May 12, 2020Assignee: BioMarin Pharmaceutical Inc.Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
-
Patent number: 10620224Abstract: Fish sexual characteristics are determined by measuring the concentration in fish serum, plasma or whole blood of one or more peptide hormones of the transforming growth factor-beta superfamily (TGF-? superfamily). The disclosed method and an accompanying field test kit may be used in sturgeon aquaculture to cull out young male fish so that increased time and resources may be devoted to the further rearing of female fish for caviar production. The method and test kit may also be used for wild fish life history studies.Type: GrantFiled: May 12, 2017Date of Patent: April 14, 2020Assignee: Mote Marine Laboratory, Inc.Inventors: Dana L. Wetzel, John E. Reynolds, William E. Roudebush